Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 11, 2001

View Archived Issues

TheraMed now called MaxCyte

FDA and EMEA accept Amevive filing for psoriasis

Modex acquires rights to novel small molecule to protect against radiation-induced skin damage

Revotar enters licensing agreement with Fraunhofer Institute for MIF

Phase II trial of Heptazyme for hepatitis C initiated

Study using Imavist for improved detection of prostate cancer set to begin

IntraBiotics presents promising results for iseganan in treating ventilator-associated pneumonia

Companies collaborate on the development of novel Alzheimer's vaccine

Endogenous brain cannabinoid is neuroprotective in mice with traumatic brain injury

Adenosine A2A receptor as a new target for antidepressant therapy

Phase I clinical trial of Esperion's RLT peptide to commence at Mayo Clinic

Cell Pathways encouraged by rapid progress made in clinical studies of CP-461 for CLL

TA-0201: a promising new drug for cardiovascular diseases

Second phase I/II clinical trial of Levulan PDT begins for treatment of Barrett's esophagus

Orally active, metabolically stable muscarinic M2 antagonist emerges from Schering-Plough screening

ICAgen seeks partners for pain management program

Orphan Medical submits amended NDA to FDA for Xyrem

Novel AEDs validated preclinically available for licensing from ICAgen

Xenova terminates TA-HSV development, DISC-PRO studies continue

Clinically used pain medication now claimed for IBS

Novel combinations claimed by Merck Frosst for depression and anxiety

Oxamide-based inhibitors of IMPDH under study at Roche

Dainippon compounds with benzodiazepine receptor subtype selectivity

Asahi Glass describes novel antiglaucoma difluoroprostaglandins

Preparation and use of new beta3-adrenoceptor agonists covered in recent patent

Thyroid hormone receptor ligands in development at Pfizer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...